Aurinia Pharmaceuticals (LTS:0UJF) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0UJF Aurinia Pharmaceuticals Inc LTS:0UJF
81 GF Score
Price C$15.41
GF Value C$13.55
! 4 Warning Signs
View Full Analysis

What is Aurinia Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

LTS:0UJF
81GF Score
Aurinia Pharmaceuticals Inc LTS:0UJF
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Aurinia Pharmaceuticals (LTS:0UJF) Overvalued in 2026?

Based on GuruFocus' analysis, Aurinia Pharmaceuticals stock appears to be overvalued. The current stock price of C$15.41 is trading 13.7% above its estimated GF Value™ of C$13.55.

Key valuation signals for LTS:0UJF:

  • FFO:
  • GF Value™: C$13.55 vs. price of C$15.41 (13.7% above fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the LTS:0UJF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aurinia Pharmaceuticals Business Description

Other Exchanges AUPH:USAIKAP:Germany
Address 14315 - 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
81GF Score

Get the complete analysis for LTS:0UJF

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$15.41
Price
C$13.55
GF Value